SCHEMBL9944237

SCHEMBL9944237

CCC(CC)Oc1cc(C(=O)Nc2ccc(C(C)=O)c(C)c2)cc(Cl)c1OC

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 3/20 0.48
TAS1R1 Q7RTX1 3/20 0.48
TAS1R2 Q8TE23 3/20 0.48
MAPT P10636 7/20 0.44
GAA P10253 2/20 0.44
LMNA P02545 1/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
ALDH1A1 P00352 3/20 0.43
HPGD P15428 1/20 0.43
NPSR1 Q6W5P4 1/20 0.42
RAB9A P51151 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
NPC1 O15118 2/20 0.42
PLAU P00749 1/20 0.42
MAPK1 P28482 1/20 0.41
POLB P06746 1/20 0.41
MCL1 Q07820 1/20 0.41
USP2 O75604 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1458204 0.93 TAS1R3 (0.47) TAS1R3TAS1R1TAS1R2MAPTGAA
SCHEMBL9944209 0.90 TAS1R3 (0.52) TAS1R3TAS1R1TAS1R2MAPTGAA
SCHEMBL9944236 0.90 TAS1R3 (0.55) TAS1R3TAS1R1TAS1R2MAPTGAA
SCHEMBL9944239 0.89 TAS1R3 (0.47) TAS1R3TAS1R1TAS1R2MAPTGAA
SCHEMBL9944320 0.86 TAS1R3 (0.47) TAS1R3TAS1R1TAS1R2MAPTGAA
SCHEMBL1458138 0.85 TAS1R3 (0.55) TAS1R3TAS1R1TAS1R2MAPTGAA
SCHEMBL9944199 0.85 TAS1R3 (0.65) TAS1R3TAS1R1TAS1R2MAPTGAA
SCHEMBL1458451 0.84 TAS1R3 (0.47) TAS1R3TAS1R1TAS1R2MAPTGAA
SCHEMBL9944193 0.83 RORC (0.49) TAS1R3TAS1R1TAS1R2MAPTGAA
SCHEMBL9944218 0.83 MAPT (0.52) MAPTGAALMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9447028-B2 Therapeutic aryl-amido-aryl compounds and their use KING'S COLLEGE LONDON (GB) 2016-09-20 US disclosed
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2016-02-11 US disclosed
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG TAS1R3 1123/4885TAS1R1 693/4885TAS1R2 808/4885
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG TAS1R3 1123/4885TAS1R1 693/4885TAS1R2 808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.